Centessa Pharmaceuticals plc (CNTA)
After hours:
| Previous close | 3.8100 |
| Open | 3.8200 |
| Bid | 0.0000 x 800 |
| Ask | 0.0000 x 1400 |
| Day's range | 3.7500 - 4.0200 |
| 52-week range | 2.8850 - 11.1900 |
| Volume | |
| Avg. volume | 116,493 |
| Market cap | 378.385M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.2950 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 5.75 |
- Globe Newswire
Centessa Pharmaceuticals Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of LB101, First LockBody® Candidate, for Solid Tumors
LB101 is a conditionally tetravalent PD-L1xCD47 LockBody bispecific monoclonal antibody being developed for solid tumorsBOSTON and LONDON, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that it has received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to initiate
- Globe Newswire
Centessa Pharmaceuticals Announces Additional 18-Months of Continued Treatment Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia
Oral presentation at American Society of Hematology (ASH) Annual Meeting highlights continued favorable safety and tolerability profile and sustained long-term efficacy results for SerpinPC: 93% reduction in median ABR for both all-bleeds and spontaneous joint bleeds in highest dose testedNo thromboembolic events or treatment-related sustained elevations of D-dimer observed Pivotal program for SerpinPC in hemophilia B advancing; PRESent-5 observation study to begin in the coming weeks BOSTON and
- Globe Newswire
Centessa Pharmaceuticals Announces New Chief People Officer Karen Anderson
BOSTON and LONDON, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for patients, today announced Karen Anderson as its new Chief People Officer. In this newly created position, Karen will lead the Company’s human resources function and help define Centessa’s people and culture strategy. Karen joins Centessa with over 25 years of experience in human reso
